{"product_id":"humanwell-business-model-canvas","title":"Humanwell Healthcare Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBusiness Model Canvas: \u003cstrong\u003e3\u003c\/strong\u003e advantages, key partners \u0026amp; revenue levers - Word\/Excel playbook\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover the strategic engine behind Humanwell Healthcare with our concise Business Model Canvas—three core advantages, key partnerships, and revenue levers mapped for quick insight. Ideal for investors and strategists wanting a ready-to-use playbook; download the full Word\/Excel canvas to act on opportunity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal API and excipient suppliers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSecure, quality-assured inputs from global API and excipient suppliers—with China and India supplying about 65% of global APIs in 2024—enable consistent production across chemical, biologic and TCM lines. Multi-sourcing across regions mitigates supply risk and price volatility while long-term GMP-compliant agreements ensure material continuity. Strategic co-development tailors inputs for anesthetics and CNS formulations, supporting faster regulatory approval and scale-up.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospitals, clinics, and GPOs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInstitutional partnerships with hospitals, clinics and GPOs—which cover over 95% of US hospitals—drive formulary inclusion and procurement scale, enabling volume contracts that often reduce unit costs by 10–25%. Clinical feedback shapes dosing forms, safety profiles and perioperative protocols, while joint stewardship programs support rational drug use and improved outcomes for anesthetics and reproductive health products.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and CRO\/CMO collaborators\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUniversities and CROs accelerate discovery, preclinical testing and clinical trials, supporting Humanwell’s CNS and reproductive programs while the global CRO market exceeded $50 billion in 2024. CMOs provide surge capacity and specialized biologics\/device modalities, with the biologics CMO segment topping $10 billion in 2024. Shared IP frameworks between partners have cut collaborative time-to-market by as much as 30% in comparable programs, broadening the pipeline while keeping fixed costs controllable.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulators and standards bodies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEarly engagement with regulators de-risks approvals across China, the US and EU and helps navigate emerging-market pathways; FDA priority review cuts median review from 10 months to 6 months, EMA centralized review averages 210 days and China's NMPA review times have fallen to around 12 months after recent reforms. Compliance partnerships ensure GMP, GCP and device standards alignment, while pharmacovigilance data sharing (VigiBase \u0026gt;30 million ICSRs) improves post-launch safety profiles and can unlock faster review\/designation pathways.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRegulatory engagement: reduces approval risk across major markets\u003c\/li\u003e\n\u003cli\u003eReview time: FDA priority 6 months vs standard 10 months; EMA ~210 days; NMPA ~12 months\u003c\/li\u003e\n\u003cli\u003eStandards alignment: GMP, GCP, device compliance\u003c\/li\u003e\n\u003cli\u003eSafety: VigiBase \u0026gt;30M reports aids pharmacovigilance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDistribution, e-commerce, and pharmacy networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNational and regional distributors extend Humanwell’s reach to roughly 18,000 pharmacies and 1,500 hospitals across China, ensuring broad shelf presence and hospital supply.\u003c\/p\u003e\n\u003cp\u003eE-commerce platforms boosted OTC and device direct-to-consumer sales, contributing to an estimated RMB 280 billion online pharma market in China in 2024.\u003c\/p\u003e\n\u003cp\u003eCold-chain logistics partners maintain biologic integrity—the global cold chain pharma market exceeded USD 200 billion in 2024—while data-sharing with distributors improves demand forecasting and cuts stockouts.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDistribution: ~18,000 pharmacies, ~1,500 hospitals\u003c\/li\u003e\n\u003cli\u003eE-commerce: RMB 280 billion China online pharma market (2024)\u003c\/li\u003e\n\u003cli\u003eCold-chain: global pharma cold chain \u0026gt; USD 200 billion (2024)\u003c\/li\u003e\n\u003cli\u003eData-sharing: reduces stockouts via improved forecasting\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSecure API\/GMP supply; hospital\/GPO reach \u003cstrong\u003e\u0026gt;95%\u003c\/strong\u003e; CRO\/CMO partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSecure multi‑source API\/excipient supplies (China\/India ~65% of APIs) and long‑term GMP contracts stabilize production and costs. Hospital\/GPO ties (covering \u0026gt;95% of US hospitals) and distributors (~18,000 pharmacies, 1,500 hospitals) drive volume and formulary access. CRO\/CMO and regulator collaborations shorten development (global CRO \u0026gt;$50B, biologics CMO \u0026gt;$10B; VigiBase \u0026gt;30M reports).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPI suppliers\u003c\/td\u003e\n\u003ctd\u003eInput security\u003c\/td\u003e\n\u003ctd\u003eChina\/India ~65% APIs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\/GPOs\u003c\/td\u003e\n\u003ctd\u003eProcurement\u003c\/td\u003e\n\u003ctd\u003eCover \u0026gt;95% US hospitals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCROs\/CMOs\u003c\/td\u003e\n\u003ctd\u003eR\u0026amp;D\/scale\u003c\/td\u003e\n\u003ctd\u003eCROs \u0026gt;$50B; CMO biologics \u0026gt;$10B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, pre-written Business Model Canvas for Humanwell Healthcare detailing 9 blocks—customer segments, value propositions, channels, relationships, revenue, key resources, activities, partners, and cost structure—with strategic narratives, competitive advantages, SWOT-linked insights, and investor-ready design to support presentations, funding discussions, and informed decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level one-page Business Model Canvas for Humanwell Healthcare that relieves the pain of fragmented strategy and lengthy formatting by condensing core components into an editable, shareable snapshot for fast collaboration and comparison.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D across chemical, biologic, and TCM\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D across chemical, biologic, and TCM targets focused discovery in anesthetics, reproductive health, and CNS indications, aligning pipelines to unmet clinical needs. Formulation science enhances bioavailability and patient adherence through optimized delivery and sustained-release technologies. Rigorous preclinical and phased clinical studies validate safety and efficacy before registration. Lifecycle management extends product value via new indications and strategic combinations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory, quality, and compliance management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMaintain GMP\/ISO systems across multi-site manufacturing to meet EU\/ICH standards and support dossier preparation and variations for multi-jurisdiction approvals, aligning with EU FMD (serialization live since 2019) and US DSCSA unit-level traceability requirements effective Nov 27, 2023. Ongoing pharmacovigilance and quality audits safeguard patients—WHO estimates up to 10% of medicines in low\/middle-income countries may be substandard or falsified. Serialization and traceability systems directly combat counterfeits and enable rapid recalls.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and supply chain orchestration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eScale of aseptic, solid dose, injectable, biologic and device lines supports commercial and CDMO demand; lean practices and automation have improved yields by ~10% and cut COGS ~15% in 2024 benchmarks. Strategic inventory and cold-chain (60-day buffer, GDP-compliant) sustain service levels, while tech transfers now enable 3–6 month capacity shifts for priority products.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercialization and market access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHEOR-driven pricing and tender strategies secure reimbursement by demonstrating cost-effectiveness against established thresholds (NICE £20,000–30,000\/QALY; ICER $100,000–150,000\/QALY), improving win rates in competitive tenders. KOL engagement converts evidence into clinical advocacy across hospital formularies. Omnichannel promotion educates HCPs and payers with targeted digital and field campaigns. Patient programs boost adherence and generate real-world evidence for lifecycle value.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHEOR: aligns pricing to NICE\/ICER thresholds\u003c\/li\u003e\n\u003cli\u003eKOLs: clinical advocacy for formulary inclusion\u003c\/li\u003e\n\u003cli\u003eOmnichannel: targeted HCP\/payer education\u003c\/li\u003e\n\u003cli\u003ePatient programs: adherence + RWE generation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational expansion and localization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eInternational expansion and localization focus on tailoring Humanwell’s portfolio to local guidelines and disease burden, prioritizing therapies aligned with regional needs; emerging markets drove ~40% of global pharma growth in 2024, highlighting opportunity. Strategic partnerships and JVs navigate distribution and regulatory nuances to shorten market entry timelines. Local packaging, labeling and language compliance ensure regulatory acceptance and uptake, while robust post-market support builds brand trust and patient adherence.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePortfolio tailoring: align with local disease burden and guidelines\u003c\/li\u003e\n\u003cli\u003ePartnerships\/JVs: manage distribution and regulatory complexity\u003c\/li\u003e\n\u003cli\u003eLocal packaging\/labeling: language and compliance\u003c\/li\u003e\n\u003cli\u003ePost-market support: drive trust and adherence\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D: anesthetics, reproductive health \u0026amp; CNS; 3 priorities; EM \u003cstrong\u003e40%\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D across anesthetics, reproductive health and CNS with TCM\/biologic pipelines, 3 priority areas and HEOR-linked indications. Multi-site GMP manufacturing improved yields ~10% and cut COGS ~15% in 2024; serialization live since 2019 and DSCSA unit traceability effective Nov 27, 2023. Commercial: HEOR thresholds NICE £20–30k\/QALY, ICER $100–150k\/QALY; emerging markets ~40% growth in 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eActivity\u003c\/th\u003e\n\u003cth\u003eKPI\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003ePriority areas\u003c\/td\u003e\n\u003ctd\u003e3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing\u003c\/td\u003e\n\u003ctd\u003eYield \/ COGS\u003c\/td\u003e\n\u003ctd\u003e+10% \/ -15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarkets\u003c\/td\u003e\n\u003ctd\u003eEmerging growth\u003c\/td\u003e\n\u003ctd\u003e40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Humanwell Healthcare Business Model Canvas shown here is the actual deliverable, not a mockup, and reflects the complete structure and content you will receive after purchase. When you complete your order, you’ll get the same editable document—ready-to-use in Word and Excel—formatted exactly as previewed. No surprises, just the full Canvas for presentation, analysis, and planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":55675017462137,"sku":"humanwell-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/humanwell-business-model-canvas.png?v=1755800069","url":"https:\/\/portersfiveforce.com\/products\/humanwell-business-model-canvas","provider":"Porter's Five Forces","version":"1.0","type":"link"}